American Society of Hirudotherapy

Transcriptomic analysis of the salivary gland of medicinal leech Hirudo nipponia

Lu Z, Shi P, You H, Liu Y, Chen S (2018) · PLoS ONE · n=0

RCT evidence detailTrial reference
GRADE Very LowInsufficient evidence

Study Profile

Design
first sialotranscriptome (salivary-gland transcriptome) analysis of Hirudo nipponia using Illumina platform; 50,535 unigenes assembled and annotated; comparison to whole-transcriptome H. medicinalis data (Chongqing Academy of Chinese Materia Medica)
Sample size (n)
0
Intervention
De novo Illumina sequencing and assembly of H. nipponia salivary-gland transcriptome
Comparator
Hirudo medicinalis whole-transcriptome reference
Primary endpoint
Identification of pharmacologically active candidate proteins in H. nipponia saliva
Primary result
84.7 million clean reads assembled into 50,535 unigenes; more than 21 genes predicted to be involved in anti-coagulatory, antithrombotic, antibacterial, anti-inflammatory, and antitumor processes; first sialotranscriptome of H. nipponia opens biotechnology pipeline for Chinese medicinal-leech-derived drug discovery
Follow-up duration
Not applicable
PMID
30339694

Key Findings

  • First sialotranscriptome of H. nipponia — 50,535 unigenes
  • More than 21 candidate pharmacologically active genes annotated
  • Established methodological template for downstream H. nipponia drug-discovery work
  • Underscores genomic distinctness of H. nipponia from H. medicinalis
  • Foundational reference for Chinese medicinal-leech research community

Limitations

  • Transcriptomic only — no protein-level validation
  • Single biological sample / pool
  • Annotation dependent on H. medicinalis reference at time of publication
  • No clinical or therapeutic translation
  • H. nipponia is not the K040187 device leech

Clinical Implications

Lu 2018 is the foundational sialotranscriptome reference for Hirudo nipponia and is cited throughout subsequent Chinese leech-pharmacology work (Shi 2023 recombinant hirudin, Kim 2023 spatial expression, Müller 2022 W. pigra cross-validation). For ASH, the paper supports the broader scientific narrative that Asian medicinal leech species harbor distinct pharmacology — without implying US K040187 clinical-practice change. Foundational research reference only.

Related Trials

Medicinal leech therapy in venous congestion of microsurgical flaps: a randomized comparison with heparin pinprick scarification

Merlino G, Carbone S, Servillo G, Marletta DA (2020)

Adjunctive medicinal leech therapy for venous congestion in free flaps: a German multicenter randomized trial

Lehnhardt M, Daigeler A, Behr B, Schmidt SV, Wallner C (2021)

Medicinal leeches and the microsurgeon: a four-year study, clinical series and risk benefit review

Whitaker IS, Josty IC, Hawkins S, Azzopardi E, Naderi N, Graf J, Damaris L, Lineaweaver WC, Kon M (2011)

Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction

Pannucci CJ, Nelson JA, Chung CU, Fischer JP, Kanchwala SK, Kovach SJ, Serletti JM, Wu LC (2014)

← Back to RCT Library

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.